Helmsley Charitable Trust

The 9th Symposium on General Population Screening for Type 1 Diabetes, hosted by the Barbara Davis Center for Diabetes at @CUAnschutz, will convene experts this week to address the challenges of identifying and supporting children with early-stage T1D.

Catch Grace Herod, PhD, Associate Program Officer in the Type 1 Diabetes Program at Helmsley, who will chair a session on Screening Implementation in Primary Care at 1PM MST on Monday, November 9, 2026.

Find the agenda here, with free virtual registration: bit.ly/3WpozfL

People with type 1 diabetes must make hundreds of extra decisions a day, every day, related to their condition, not just during clinic visits. This National Diabetes Awareness Month, we’re spotlighting the organizations and people working to make those days easier.

We affirm our commitment to a future where everyone can access quality care — no matter where they live. Learn more about some of our work in the U.S.: bit.ly/4znnlQL

It’s Medical Ultrasound Awareness Month, and we’re celebrating the meaningful role these small but powerful devices play in our goal to ensure rural communities have access to the highest quality of care close to home.

#MUAM

More than 800 years ago, Indigenous peoples built earthen mounds along the Mississippi River. Many are shaped like animals, including bears, birds, and bison.

The Effigy Mounds National Monument, in northeastern Iowa, protects and preserves more than 200 of these ancient mounds. The site holds deep cultural and spiritual meaning for the monument’s 20 affiliated tribal nations.

Now, the @NatlParkService, the local community, and the affiliated tribal nations will work together to tell the story of this historic site.

With Helmsley’s support, new exhibits and a 20-minute film at the monument’s renovated visitor center will share a truthful account of the site’s cultural history, alongside its geological, archaeological, and historic significance.

Press event photos by Alex Cooney for the @NationalParkFdn.

Learn more: helmsleytrust.org/news-and-insig…

Researchers at @WeillCornell @WCM_IBD found that patients with mild-to-moderate inflammatory bowel disease had a healthier gut microbiome after taking fluconazole, an antifungal medication. Treatment caused positive changes in both bacterial and fungal populations and was also associated with improved IBD symptoms.

The findings now need to be confirmed in a larger, placebo-controlled trial but they offer a potential framework for developing more precise, mycobiome-guided treatments for IBD in the future.

Learn more: news.weill.cornell.edu/news/2026/09/a…